Investors

At a Glance

Lexaria Bioscience Corp. (CSE:LXX; OTCQB:LXRP) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECH™ technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034.

Collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. Each of cannabinoids (such as CBD and THC); vitamins; NSAIDs and nicotine are being studied.

VIDEO – LEXARIA BIOSCIENCE, IMPROVING ABSORPTION AND POTENCY OF MEDICAL CANNABINOIDS

VIDEO – IMPROVING THE DELIVERY FOR MEDICAL CANNABINOIDS – LEXARIA BIOSCIENCES

Lexaria Bioscience Corp. | Cannabis Research |

First applications for the technology are being used in the legal cannabinoid consumer products space, which is expected to show Compounded Annual Growth Rate (CAGR) of more than 25% through 2021 in North America.

Lexaria Bioscience Corp. | Cannabis Research |

Growth estimates for the legal cannabis industry put it in an elite group of industries that achieved $5 billion in annual revenue and then grew at a > 25% CAGR for the next 5 years.

Investor FAQs 

 

What is Lexaria’s ticker symbol and where do the shares trade?

Lexaria Bioscience trades on the Canadian Securities exchange under the symbol LXX and on the OTCQB under the symbol LXRP.

 

What is Lexaria’s CUSIP number?

Lexaria’sCUSIP number is 52886N.

 

When is Lexaria’s fiscal year end?

Lexaria’s fiscal year end is August 31.

 

When is the next annual general meeting?

The next annual general meeting will be announced when available.

 

Who are Lexaria’s external auditors?

MNP LLP act as Lexaria’s external auditors.

 

Who is Lexaria’s Transfer Agent?

Lexaria’s transfer agent is Computershare Investor Services Inc.

Web: www.computershare.com

Phone: (800) 564-6253

 

Contact

Shareholder and Investor Relations Contact

Alex Blanchard

Manager Corporate Communications and Investor Relations

778-796-1897

[email protected]

Share Structure

As at:2017-06-22
Shares issued and outstanding 66,972,303
Options Granted 3,375,875
Warrants outstanding 8,988,031
Fully diluted 79,336,209
Insider ownership – fully diluted 16,985,549

 

Events

DateConference NameLocation
September 1-2, 2017Investorshub International Cannabis ConferenceLos Angeles
September 7-8, 2017IC3Miami
September 30, 2017NAI ConferenceToronto
October 12-14, 2017SWCC PhoenixPhoenix
October 14, 2017NAI ConferenceVancouver
November 14-17, 2017Marijuana Business Conference and ExpoLas Vegas
December 5-7, 2017LD MicroLos Angeles
February 1-2, 2018International Cannabis Business ConferenceSan Francisco
April 12-13, 2018International Cannabis Business ConferenceBerlin

 

Stock Quotes

LXRP: OTCQB – http://www.otcmarkets.com/stock/LXRP/quote

LXX: CSE – http://thecse.com/en/listings/diversified-industries/lexaria-corp

Auditors:
Davidson & Company LLP
1200 – 609 Granville St
PO Box 10372, Pacific Centre
Vancouver BC
Canada V7Y1G6

Corporate Lawyers:
Macdonald Tuskey
Suite 400, 570 Granville Street
Vancouver BC Canada
V6C 3P1
www.macdonaldtuskey.com

Intellectual Property Lawyers:
Fisher Broyles
6000 Fairview Road
Suite 1200
Charlotte, NC  28210
U.S.A.
www.fisherbroyles.com

Trademark Lawyers:
Fenno Law Firm, LLC
171 Church Street
Suite 160
Charleston, SC 29401
www.fennolaw.com